Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Spotlight Therapeutics is a pioneering biotechnology company focused on developing a new class of medicines using its proprietary TAGE™ (Targeted Active Gene Editors) platform. This platform is designed for cell-targeted in vivo CRISPR gene editing, aiming to deliver one-time, curative therapies for debilitating genetic diseases. The company's research spans several therapeutic areas, including immuno-oncology, ophthalmic diseases, hemoglobinopathies, and immunology, with the goal of directly correcting the root cause of genetic disorders within the patient's body.
Primary research and development (R&D) laboratories and corporate operations, including scientific discovery, preclinical development, and strategic management.
State-of-the-art laboratory facilities specifically designed and equipped for advanced CRISPR gene editing research and development.
An innovative, collaborative, and science-driven environment. The culture emphasizes scientific rigor, rapid advancement of therapeutic programs, and a strong commitment to addressing unmet patient needs through cutting-edge genetic medicine. Expect a dynamic, fast-paced startup atmosphere.
Strategically located in the San Francisco Bay Area, a leading global hub for biotechnology, providing access to a rich ecosystem of talent, research institutions, and potential collaborators. The headquarters serves as the central node for all company operations and innovation.
Spotlight Therapeutics is primarily based in the United States, with its headquarters and core R&D operations located in Alameda, California. While its physical presence is concentrated in the US, its scientific collaborations, potential future clinical trials, and engagement with the global scientific and investment communities may extend internationally. The company's TAGE™ platform aims to develop therapies for genetic diseases with a global patient population.
2 West Point Avenue, Suite 110
Alameda
CA
United States
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Spotlight Therapeutics' leadership includes:
Spotlight Therapeutics has been backed by several prominent investors over the years, including:
Spotlight Therapeutics has been actively strengthening its executive leadership. A key appointment in scientific leadership (CSO) occurred in May 2023. Other significant C-suite additions (CMO, CFO) occurred in early 2023, slightly predating the strict 12-month window but contributing to the current robust executive team.
Discover the tools Spotlight Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Spotlight Therapeutics likely utilizes common corporate email formats. While not publicly confirmed, patterns such as [first_initial][last]@[domain] or [first].[last]@[domain] are frequently used in the biotech industry.
[first_initial][last]@spotlighttx.com
Format
pcameron@spotlighttx.com
Example
80%
Success rate
spotlighttx.com • November 1, 2023
Spotlight Therapeutics shared promising preclinical data on its TAGE™ (Targeted Active Gene Editors) platform at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, highlighting advancements in its in vivo gene editing technology....more
spotlighttx.com • May 17, 2023
The company presented new preclinical findings from its TAGE™ platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, demonstrating progress in developing cell-targeted in vivo CRISPR gene editing therapies....more
spotlighttx.com • May 1, 2023
Spotlight Therapeutics announced the appointment of Peter Cameron, Ph.D., as its new Chief Scientific Officer to spearhead its research and development strategy....more
spotlighttx.com • November 29, 2021
Spotlight Therapeutics successfully closed a $36.5 million Series B financing round co-led by GordonMD Global Investments and EPIQ Capital Group, with participation from existing investors, to advance its TAGE platform and pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Spotlight Therapeutics, are just a search away.